Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

Chemicals and materials maker DuPont (DD) is rallying 7% after posting stronger-than-expected fourth quarter financial ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...